Matt Hoffman

The investigators concluded that these findings have implications which suggest that transferring patients for late-window thrombectomy is associated with substantial clinical benefits and should be strongly encouraged.

The director of the mitochondrial research program at Akron Children’s Hospital spoke about how to best manage a condition such as PMM, where there are no FDA-approved therapies.

The study provided Class I evidence that the ALSDI can help the confirmation and diagnosis of ALS and its mimicking conditions at the earliest stages of the disease, when therapeutic efforts are most efficacious.

The neurosurgeon at The Ohio State University Wexner Medical Center and lead investigator of the first-in-world trial spoke about the study’s goals and the potential of the treatment.

The microdystrophin gene transfer therapy from Solid Biosciences has shown protein expression in the first 3 patients dosed. As a result, the company is expediting the planned dose-escalating activities.

Findings from a cross-sectional exploration have suggested that biological differences between men and women may explain the higher risk for Alzheimer faced by women.

The executive vice president and chief medical officer of Zogenix spoke about what sets the fenfluramine agent apart and what clinicians need to know after its NDA submission.

The professor of pediatrics at Northeast Ohio Medical University and the director of the NeuroDevelopmental Science Center at Akron Children’s Hospital provided insight into the therapeutic landscape of PMM.

The Medtronic product will now be available for use with patients with small or medium wide-necked aneurysms in the area from the petrous to the terminus of the internal carotid.

The stroke specialist at the Cerebrovascular Center at Cleveland Clinic detailed how patients who were rehabilitated earlier were shown to have better outcomes and a shorter stay in the intensive care unit in this study.

The NDA for Zogenix's fenfluramine therapy is supported by data from 2 phase 3 trials in Dravet syndrome, as well as an interim analysis from the company’s ongoing open-label extension study, which includes 232 patients treated for up to 21 months.

The ELLDOPA trial results showed no significant difference with levodopa in combination with carbidopa between the patients who were treated early compared to those with delayed initiation.

The principal medical science director at Genentech spoke about how Floodlight works for physicians and patients and how it could improve care in MS.

A phase 3 trial of the therapy is ongoing after a number of positive signs from earlier assessments. Thus far, the tetrapeptide has shown potential to become the first treatment for PMM.

The phase 2 trial for the CGRP receptor agonist is planned for Q2 of 2019 after the intranasal treatment met its target therapeutic exposures in phase 1. Biohaven submitted an IND to the FDA in September 2018.

According to physician-reported data, the wearable PKG device provided data which resulted in an alteration in Parkinson management for 32% of patients.

The phase 1 trial assessed high doses of the therapy in 24 healthy volunteers, divvied up into 4 cohorts to receive doses, including 36 mg/kg, 60 mg/kg, 85 mg/kg, and 110 mg/kg. These data build upon the findings of the phase 2b CHANGE-MS trial.

The recall began in October 2018, was initiated due to a mislabeling on the pre-printed content on the infusion bag for lot ABD807. Thus far, there have been no reported adverse events related to this recall.

The acute administration of adhesive dermally applied microarray zolmitriptan (Qytripta, Zosano Pharma) showed an almost uniform benefit across subgroups of patients with severe pain, delayed treatment, nausea, and who were awakening with headache.

The pediatric epileptologist and adjunct professor of pediatrics at the University of Calgary spoke about how broaching the topic of SUDEP has gone from undiscussed to a guideline-mandated practice in epilepsy.

The chief scientific officer of Cortexyme detailed the findings of a study that suggested that Porphyromonas gingivalis plays a role as a driver of Alzheimer disease pathology.

The David M. Levy Professor of Neurology and director of the Center for Health and Technology at the University of Rochester Medical Center spoke about the projection for the future and what could be done to mitigate it.

The regulatory agency determined that it was unable to approve the treatment in its present form, requesting additional information and analyses but no additional clinical studies.

The Independent Monitoring Committee’s interim analysis suggested that the treatment was unlikely to meet the trials’ primary end point of change from baseline in Clinical Dementia Rating-Sum of Boxes score.

The model showed that sporadic Alzheimer cells differentiated in an accelerated fashion in early development, as well as irregularities in the REST protein.

Data has suggested that patients with multiple sclerosis who have withdrawn from treatment with fingolimod (Gilenya, Novartis) can safely be treated effectively with alemtuzumab (Lemtrada, Sanofi Genzyme) or rituximab (Rituxan, Genentech/Biogen).

Despite the non-significant differences between groups, a slight trend toward a dementia risk reduction has led to the Alzheimer’s Association providing funds for a follow-up extension trial, dubbed SPRINT-MIND 2.0.

The chief of the Division of Immunotherapy at the Northwestern University Feinberg School of Medicine discussed the results of the randomized clinical trial and the implications of this treatment in clinical practice.

The postgraduate epidemiology fellow at the Centers for Disease Control and Prevention discussed the data and what she and her colleagues found in their analyses of children with Tourette syndrome.

Nonmyeloablative hematopoietic stem cell transplantation showed less disease progression in relapsing multiple sclerosis patients after 1 year compared to a number of FDA-approved disease-modifying therapies.